Ra Pharmaceuticals (Ra Pharmaceuticals) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2019)

View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Ra Pharmaceuticals's annualized Gross Profit for the quarter that ended in Dec. 2019 was $0.00 Mil. Ra Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2019 was $296.55 Mil. Therefore, Ra Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2019 was 0.00%.

Ra Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Ra Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Gross-Profit-to-Asset % Chart

Ra Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

25.86

6.52

1.67

1.19

Ra Pharmaceuticals Quarterly Data
	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
Gross-Profit-to-Asset %	Get a 7-Day Free Trial														6.45	-	-	4.82	-

Competitive Comparison of Ra Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Ra Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ra Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Ra Pharmaceuticals's Gross-Profit-to-Asset % falls into.

Ra Pharmaceuticals Gross-Profit-to-Asset % Calculation

Ra Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2019 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2019 )	/	( (Total Assets (A: Dec. 2018 )	+	Total Assets (A: Dec. 2019 ))	/ count )
	=	3	/	( (219.22	+	284.152)	/ 2 )
	=	3	/	251.686
	=	1.19 %

Ra Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2019 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2019 )	/	( (Total Assets (Q: Sep. 2019 )	+	Total Assets (Q: Dec. 2019 ))	/ count )
	=	0	/	( (308.938	+	284.152)	/ 2 )
	=	0	/	296.545
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2019) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Ra Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

87 Cambridge Park Drive, Cambridge, MA, USA, 02140

Website

http://www.rapharma.com

Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.

Executives

Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco	director, officer: President and CEO	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins	10 percent owner
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner	officer: Executive VP and CFO	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472